Comparison of Residual Risk–Based Eligibility vs Tumor Size and Nodal Status for Power Estimates in Adjuvant Trials of Breast Cancer Therapies

IMPORTANCE: Many large adjuvant clinical trials end up underpowered because of fewer than expected events in the control arm. Ensuring a minimum number of events would result in more informative trials. OBJECTIVE: To calculate individualized residual risk estimates using residual risk prediction sof...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JAMA Oncol
Autors principals: Wei, Wei, Kurita, Tomoko, Hess, Kenneth R., Sanft, Tara, Szekely, Borbala, Hatzis, Christos, Pusztai, Lajos
Format: Artigo
Idioma:Inglês
Publicat: American Medical Association 2018
Matèries:
Original Investigation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5885272/
https://ncbi.nlm.nih.gov/pubmed/29372234
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2017.5092
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars